Highlights A lower incidence of Parkinson’s disease has been observed in diabetic patients taking DDP-4 and GLP-1 receptor agonists, when compared to diabetic patients undergoing other forms of therapy. Even a short-term use of these medications showed a significant protective effect against Parkinson’s disease. Need for the study Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease. A variety of genetic, environmental, and demographic risk factors contribute to a person’s risk of Parkinson’s disease.
Recent studies have revealed a significant risk of PD in diabetic patients especially those with type 2 diabetes mellitus 1 . Additionally, antidiabetic drugs have also been found to play a crucial role in the incidence of PD 2 . Recent small-scale animal and clinical studies have demonstrated the neuroprotective effects of glucagon-like peptide-1 receptor (GLP-1R)…
